Why the study?
Does oral continuous 17β-estradiol plus norethisterone acetate replacement therapy improve abdominal subcutaneous fat, serum leptin levels, and body composition in postmenopausal women?
Does oral continuous 17β-estradiol plus norethisterone acetate replacement therapy improve abdominal subcutaneous fat, serum leptin levels, and body composition in postmenopausal women?
Oral continuous combined E2/NETA replacement therapy reduces central fat accumulation and attenuates leptin increases in postmenopausal women, potentially offering cardiovascular and metabolic protection.
Answers are grounded in this paper and cite their sources.
Supports oral E2/NETA to limit central adiposity in postmenopausal women; extends evidence on combined HRT cardiometabolic effects.
Oral continuous combined regimen of E2/NETA significantly reduced central fat accumulation as assessed by WC and STh, and attenuated the increase in SLL. The observed changes in SLL were highly and positively related to changes in STh. The oral continuous combined E2/NETA regimen appears to have protective effects on cardiovascular function and probably on metabolic diseases by its slimming effect upon WC in postmenopausal women.
No takes yet. Share an insight, caveat, or question.
̈ksel et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: